Is Cencora (COR) a risky stock?
As of July 21, 2026, Clavix grades Cencora (COR) C+ for risk, a composite score of 62 out of 100 on an A+ to F scale, which puts COR in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind COR's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how COR scores on each, as of July 21, 2026.
What's moving COR's risk right now
Company-specific signals Clavix flags behind COR's current grade, drawn from recent news and filings as of July 21, 2026.
Swiss National Bank raised its Cencora stake 7.2% to about $169.9 million in Q1. Australian fund Aware Super also opened a new $5.18 million position, both signaling continued institutional confidence in the drug distributor.
What a C+ grade means
On the Clavix A+ to F scale, COR's composite of 62 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell COR or any security. Grades are risk indicators, not predictions of return. Data may be delayed.